Ashok Leyland reported a 38.4% year-on-year rise in standalone net profit at Rs 1,245.87 crore for the quarter ended March 2025, compared to Rs 900.41 crore in the same period last year.

Ashok Leyland Q4 PAT jumps 38% YoY to Rs 1,246 cr; declares 1:1 bonus issue

Capital Market Automatic


The diverse delegation features BJP MPs Tejasvi Surya, Shashank Mani Tripathi, and Bhubaneswar Kalita, along with LJPs Shambhavi Choudhary, TDPs GM Harish Balayogi, Shiv Senas Milind Deora, JMMs Sarfaraz Ahmad, and former ambassador Taranjit Singh Sandhu. Their first stop: New York, where they will pay tribute at the 9/11 Memorial, followed by a visit to Guyana for its Independence Day celebrations.


Tharoor leads all-party delegation to US, labels Pakistan a 'terror-exporting state'

Securities and Exchange Board of India, Sebi

Category II AIFs can now invest in listed debt securities rated 'A' or below, offering more flexibility and investment opportunities

SEBI eases norms for Category II AIFs on debt securities investments

Business Standard

To set up greenfield manufacturing in Ratnagiri, Maharashtra

Reliance Defence announces strategic partnership with Dseldorf based Rheinmetall AG

Board of Advani Hotels & Resorts (India) recommends 2nd interim dividend

Dapic Metropolis Healthcare (formerly known as Metropolis Histoxpert Digital Services), a wholly owned subsidiary of Metropolis Healthcare, has completed the acquisition of entire business of Dr. Ahujas' Pathology & Imaging Centre (DAPIC  a partnership firm), Dr. Alok Ahuja and Dr. Alka Ahuja (collectively referred to as acquired business) as a going-concern, effective 23 May 2025, in accordance with the terms agreed under the Business Transfer Agreement. 

Metropolis Healthcare completes acquisition of Dr. Ahujas' Pathology & Imaging Centre

Dalal Street Investments reports standalone net loss of Rs 0.41 crore in the March 2025 quarter

Premier reports consolidated net loss of Rs 2.33 crore in the March 2025 quarter

Ashoka Buildcon consolidated net profit rises 73.15% in the March 2025 quarter


Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. 


Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.

Companies News: Get latest company news, company results, company interviews, company financials, company analysis, company disclosure, corporate news, company announcements at Business Standard.

Company News: Company Business News, Indian Companies News, Company Analysis, Corporate Industry News

Get latest company news, company results, company interviews, company financials, company analysis, company disclosure, corporate news, company announcements at Business Standard.

Colinz Laboratories Ltd News